Page last updated: 2024-09-04

bb3497 and actinonin

bb3497 has been researched along with actinonin in 5 studies

Compound Research Comparison

Studies
(bb3497)
Trials
(bb3497)
Recent Studies (post-2010)
(bb3497)
Studies
(actinonin)
Trials
(actinonin)
Recent Studies (post-2010) (actinonin)
1302166057

Protein Interaction Comparison

ProteinTaxonomybb3497 (IC50)actinonin (IC50)
Urokinase-type plasminogen activatorHomo sapiens (human)0.14
Interstitial collagenaseHomo sapiens (human)1.1
NeprilysinOryctolagus cuniculus (rabbit)8.2
72 kDa type IV collagenaseHomo sapiens (human)3
Stromelysin-1Homo sapiens (human)6
NeprilysinHomo sapiens (human)6.7
Aminopeptidase NHomo sapiens (human)0.4
Peptide deformylaseStaphylococcus aureus subsp. aureus Mu500.005
Peptide deformylaseStaphylococcus aureus0.02
Peptide deformylase 1A, chloroplastic/mitochondrialArabidopsis thaliana (thale cress)0.027
Peptide deformylase, mitochondrialHomo sapiens (human)0.5622
Peptide deformylase Escherichia coli0.052

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Beckett, RP; Davies, SJ; Launchbury, SB; Miller, A; Pratt, LM; Spavold, ZM; Todd, RS; Whittaker, M1
Canaan, S; Cavalier, JF; Magrioti, V; Mallick, I; Mavrikaki, V; Pagonis, A; Poncin, I1
Baker, PJ; Barynin, V; Beckett, RP; Brown, A; Catlin, G; Clements, JM; Hunter, MG; Lobell, M; Palan, S; Rice, DW; Rodgers, HF; Salama, S; Thomas, W; Whittaker, M; Wood, S1
Kanwar, AJ; Khuller, GK; Sharma, A; Sharma, S2

Other Studies

5 other study(ies) available for bb3497 and actinonin

ArticleYear
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.
    Bioorganic & medicinal chemistry letters, 2001, Oct-08, Volume: 11, Issue:19

    Topics: Amidohydrolases; Aminopeptidases; Anti-Bacterial Agents; Crystallography, X-Ray; Enzyme Inhibitors; Hydroxamic Acids; Molecular Conformation; Structure-Activity Relationship

2001
Design, synthesis and antibacterial activity against pathogenic mycobacteria of conjugated hydroxamic acids, hydrazides and O-alkyl/O-acyl protected hydroxamic derivatives.
    Bioorganic & medicinal chemistry letters, 2022, 05-15, Volume: 64

    Topics: Animals; Anti-Bacterial Agents; Hydrazines; Hydroxamic Acids; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Structure-Activity Relationship

2022
Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:2

    Topics: Amidohydrolases; Aminopeptidases; Animals; Anti-Bacterial Agents; Crystallography, X-Ray; Drug Resistance, Microbial; Enzyme Inhibitors; Escherichia coli; Hydroxamic Acids; Microbial Sensitivity Tests; Mutation; Rats; Reverse Transcriptase Polymerase Chain Reaction; Time Factors

2001
In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv.
    International journal of antimicrobial agents, 2009, Volume: 34, Issue:3

    Topics: Amidohydrolases; Animals; Antibiotics, Antitubercular; Dipeptides; Drug Synergism; Drug Therapy, Combination; Hydroxamic Acids; Hydroxylamine; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Phenanthrolines; Protease Inhibitors; Rifampin; Tuberculosis

2009
Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis.
    The Journal of infection, 2010, Volume: 60, Issue:6

    Topics: Amidohydrolases; Analysis of Variance; Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Enzyme Inhibitors; Hydroxamic Acids; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Rifampin; Tuberculosis

2010